137 related articles for article (PubMed ID: 18231794)
1. Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren's syndrome.
Stewart C; Cha S; Caudle RM; Berg K; Katz J
Rheumatol Int; 2008 Jun; 28(8):771-6. PubMed ID: 18231794
[TBL] [Abstract][Full Text] [Related]
2. Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations With Extraglandular Involvement and Disease Activity in Sjögren's Syndrome.
Kanne AM; Jülich M; Mahmutovic A; Tröster I; Sehnert B; Urbonaviciute V; Voll RE; Kollert F
Arthritis Care Res (Hoboken); 2018 Jun; 70(6):944-948. PubMed ID: 28941024
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome.
Fujihara T; Takeuchi T; Tsubota K; Kayagaki N; Yagita H; Okumura K; Abe T
Clin Rheumatol; 1998; 17(6):496-9. PubMed ID: 9890678
[TBL] [Abstract][Full Text] [Related]
4. Receptor of advanced glycation end product (RAGE) expression in the minor salivary glands of patients with Sjögren's syndrome: a preliminary study.
Katz J; Stavropoulos F; Bhattacharyya I; Stewart C; Perez FM; Caudle RM
Scand J Rheumatol; 2004; 33(3):174-8. PubMed ID: 15228188
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble adhesion molecules (sICAM-1, sVCAM-1, sE-selectin) and neopterin in patients with Sjögren's syndrome.
Andrýs C; Krejsek J; Slezák R; Drahosová M; Kopecký O
Acta Medica (Hradec Kralove); 1999; 42(3):97-101. PubMed ID: 10677896
[TBL] [Abstract][Full Text] [Related]
6. Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome.
Sawada S; Sugai S; Iijima S; Takei M; Paredes E; Hayama T; Nishinarita S; Hosokawa Y; Horie T; Obara T
Am J Med; 1992 Feb; 92(2):134-40. PubMed ID: 1543196
[TBL] [Abstract][Full Text] [Related]
7. Investigation of novel autoantibodies in Sjogren's syndrome utilizing Sera from the Sjogren's international collaborative clinical alliance cohort.
Suresh L; Malyavantham K; Shen L; Ambrus JL
BMC Ophthalmol; 2015 Apr; 15():38. PubMed ID: 25881294
[TBL] [Abstract][Full Text] [Related]
8. Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.
Cheng Y; Zhong J; Xiang Y; Zeng F; Cai D; Zhao L
Clin Interv Aging; 2014; 9():1981-6. PubMed ID: 25429209
[TBL] [Abstract][Full Text] [Related]
9. Serum level of IL-6 in patients with primary and secondary Sjögren's syndrome.
Slezák R; Krejsek J; Kopecký O; Jelenová H
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(2):59-60. PubMed ID: 8584859
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-2 receptor in primary and secondary Sjögren's syndrome.
Tomás S; Coll J; Palazón X
Br J Rheumatol; 1997 Feb; 36(2):194-7. PubMed ID: 9133928
[TBL] [Abstract][Full Text] [Related]
11. The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases.
Delrue C; Speeckaert R; Delanghe JR; Speeckaert MM
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769213
[TBL] [Abstract][Full Text] [Related]
12. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
Melin EO; Dereke J; Hillman M
Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
[TBL] [Abstract][Full Text] [Related]
13. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels.
Gaens KH; Ferreira I; van der Kallen CJ; van Greevenbroek MM; Blaak EE; Feskens EJ; Dekker JM; Nijpels G; Heine RJ; 't Hart LM; de Groot PG; Stehouwer CD; Schalkwijk CG
J Clin Endocrinol Metab; 2009 Dec; 94(12):5174-80. PubMed ID: 19890027
[TBL] [Abstract][Full Text] [Related]
14. IL-14α as a Putative Biomarker for Stratification of Dry Eye in Primary Sjögren's Syndrome.
Liang Y; Xian Z; Fu D; Liu S; Yao Y; Jin Y; Gao C; Shen L; Shi G; He J
Front Immunol; 2021; 12():673658. PubMed ID: 34012457
[TBL] [Abstract][Full Text] [Related]
15. Serum IgA against type 3 muscarinic acetylcholine receptor is a novel marker in diagnosis of Sjögren's syndrome.
Li YN; Guo JP; He J; Liu X; Yin FR; Ding Y; Yao HH; Kang AJ; Li ZG
Chin Med J (Engl); 2011 Aug; 124(16):2490-5. PubMed ID: 21933593
[TBL] [Abstract][Full Text] [Related]
16. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
17. Soluble receptor for advanced glycation end products as a vasculopathy biomarker in sickle cell disease.
Safwat NA; Kenny MA
Pediatr Res; 2018 Dec; 84(6):869-874. PubMed ID: 30367158
[TBL] [Abstract][Full Text] [Related]
18. High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome.
Ramos-Casals M; Font J; García-Carrasco M; Calvo J; Places L; Padilla O; Cervera R; Bowen MA; Lozano F; Ingelmo M
Rheumatology (Oxford); 2001 Sep; 40(9):1056-9. PubMed ID: 11561119
[TBL] [Abstract][Full Text] [Related]
19. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
[TBL] [Abstract][Full Text] [Related]
20. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer.
Jing R; Cui M; Wang J; Wang H
Neoplasma; 2010; 57(1):55-61. PubMed ID: 19895173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
